The cumulative incidence of myocardial infarction was slightly higher in the PDT and pegaptanib groups than in the bevacizumab and ranibizumab groups, but the overall P value did not reach statistical significance.
← all excerpts
The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273-1279.
1
—
—